CALR and cancer: developed a pro‐phagocytic nanoparticle (SNPACALR&aCD47) system to co‐deliver anti‐CD47 and CALR.[221] Anti‐CD47 antibody could block CD47‐SIRPα to promote the macrophages to “eat” tumor cells, meanwhile the CALR can amplify the tumor‐phagocytosis of macrophages and eventually enhance the macrophage‐based cancer immunotherapy.